Technical Data
C7904-70F
COX 1 (Cyclooxygenase-1, PGHS-1, Prostaglandin Endoperoxide Synthase-1, PHS 1, Ovarian Cancer Marker)
Description:
Cyclooxygenases 1 and 2 (COX-1, COX-2) are enzymes involved in the conversion of arichidonate to prostaglandins. COX-1 and COX-2 are very similar in structure and function, though they vary in expression. COX-1 is normally expressed in most cell types, whereas COX-2 expression is at low levels unless induced by hormonal stimuli. The apparent molecular weight of COX-1 appears to be around 72kD.

The prostanoid family includes PGD2, PGE2, PGF2alpha, PGI2, thromboxane A2 and prostaglandins. The prostaglandins (PGs) are implicated in various physiological and pathophysiological events, including male fertility, menstruation, ovulation, pregnancy, implantation and inflamatory and neoplastic diseases. The biosynthesis of PGs and some other prostanoids, is catalyzed in a rate limiting step by PG-H synthase (also known as cyclooxygenase (COX), PG-endoperoxidase synthase (PTGS)) which converts arachiodonic acid to prostaglandin/prostanoid precursor PGH2. Two cyclooxygenase isozymes, COX1 (human, 576aa, 69-72kD; chromosome 9) and COX2 (human, 604aa, 74kD; chromosome 1) have been identified. COX1, a constitutively expressed isoform, produces physiologically relevant prostanoids such as those in stomach and platelets. COX2 isoform is inducible and rapidly upregulated at inflamation sites and forms proinflamatory prostanoids. The overexpression of COX-2 also leads to tumerogenesis. Recently, a third isoform COX3 (canine 633aa; ~65kD in human aorta) has been reported. Two smaller COX1-derived proteins (partial COX1) PCOX1a (canine 414aa, ~53kD in human aorta) and PCOX1b have also been characterized. The COX3, but not PCOX1a, possesses glycosylation dependent cyclooxygenase activity. The nonsteroidal antiinflammatory drugs (NSAIDs) reduce the formation of prostaglandins by inhibiting the activity of cyclooxygenases (COX1, COX2 and COX3), This ability was associated with inhibition of COX, which converts arachidonic acid to the prostaglandin precursor prostaglandin H2.

Applications:
Suitable for use in ELISA, Immunohistochemistry, Immunofluorescence and Western Blot. Other applications have not been tested.

Recommended Dilution:
ELISA: 0.1-1ug/ml
Immunohistochemistry (frozen and paraffin): 10-20ug/ml
Immunofluorescence: 10-20ug/ml
Western Blot: 2.5-5ug/ml
Optimal dilutions to be determined by the researcher.

Positive Controls:
Human platelets, mouse and rat macrophages.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG2b,k6A52Affinity Purified
SizeStorageShippingSourceHost
100ug4C (-20C Glycerol)Blue IceHumanMouse
Concentration:
~0.5mg/ml
Immunogen:
Ram testes
Purity:
Purified by Protein A chromatography
Form
Supplied as a liquid in PBS, pH 7.4, 0.1% sodium azide
Specificity:
Recognizes COX-1at 72kD. Crossreactivity: to a moderate degree with ovine COX-2, and minimally with human COX-2. Species Crossreactivity: ovine, human, mouse, and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Charpigny, et al. Endocrinology 138(5):2163-2171, 1997. 2. Ballif, et al. PNAS 93:5544-5549, 1996.